Back to search

University of Crete (UOC)

Μελέτη της ωφελιμότητας της λήψης κουερσετίνης (quercetin) σε διαβητικούς ασθενείς υπό αγωγή με αντιδιαβητικά δισκία: μία τυχαιοποιημένη προοπτική μελέτη δύο βραχιόνων (two –arm, prospective randomized control clinical trial) (interventional vs observation arm) στην Πρωτοβάθμια Φροντίδα Υγείας

Abstract

dc:description

Introduction: Diabetes, a rapidly developing morbidity with high global prevalence, is associated with dysglycemia that often leads to complications. This major chronic metabolic disease, characterized as an age-related disease, necessitates effective interventions. Patients with type 2 diabetes mellitus (T2DM) often experience elevated levels of anxiety, impacting their quality of life and disease management. Quercetin, a bioactive flavonoid found in a variety of plant foods such as apples, berries, cabbage, and prickly pears, exhibits significant antioxidant and anti-inflammatory activity. It has garnered scientific interest due to its potential beneficial pleiotropic, therapeutic properties. Telomeres, the protective chromosomal ends, progressively shorten and are potentially involved in the pathogenesis of age-related diseases. In T2DM, telomere shortening may play a significant role, but the overall ‘picture’ remains limited. Considering these, we aimed to examine the potential benefit of quercetin on bioclinical measurements and health parameters, as well as its influence on telomere length (TL) dynamics in patients with T2DM.Methods: This prospective randomized controlled trial investigated the clinical utility of quercetin in patients with T2DM, enrolled as population of responsibility of the 4th TOMY (Local Health Unit) of Heraklion and receiving non-insulin antidiabetic treatment. One hundred participants were stratified by age and sex (1:1) and randomized to control (n = 50) or intervention (n = 50) groups. The control received standard care only, while the intervention received 500 mg of quercetin daily for 12 weeks, followed by an 8-week washout and a final consecutive 12-week supplementation period (total: 32 weeks), as adjunct to their usual care. Meetings were held at baseline, at an intermediate time point (3 months) and at the end of the study (8 months). To capture aspects of early efficacy and clinical safety of quercetin administration in patients with T2DM, an interim follow-up at 12 weeks was performed in a randomized subsample of patients and data from 38 patients were analyzed (intervention: 20, control: 18). All participants provided informed, signed consent for the collection of anthropometric measurements, vital signs, daily habits data, and PiKo-6 spirometric measurements. In addition, participants answered the Short Anxiety Screening Test (SAST) questionnaire and the 36-Item Short Form Health Survey (SF-36). As part of the main study, comprehensive health assessments, including blood tests, were carried out at baseline and completion. Quality of life and anxiety were assessed using the 36-item Short Form Health Survey (SF-36) and the Short Anxiety Screening Test (SAST-10). Data on possible adverse events were collected throughout the study, according to the CONSORT standard. Of the 88 patients completing the trial, 82 consented to blood sampling for TL measurements (baseline and study endpoint). Whole blood absolute TL measurements using quantitative polymerase chain reaction (qPCR) were conducted. Statistical analyses were performed to identify differences in the mean values of laboratory tests in the studied groups, univariate and multivariate regression to investigate the association of quercetin intake and markers of cellular aging. Results: The interim analysis included 38 participants (60% men and 40% women in the intervention group, 38.9% men and 61.1% women in the control group). In the treatment arm, the forced expiratory volume in the first second (FEV1) measured by PiKo-6 showed a Δ%- change for the intervention arm: +6.8% (INT), control (CON): -0.2% (p = 0.059), systolic arterial pressure; INT: -7.4%, CON: -3.7% (p = 0.117), waist circumference; INT: -1.5% CON: -0.7% (p=0.455) and night sleep, INT: +5.3%, CON: +1.4% (p = 0.926) were positively affected. The treatment group showed significant improvements in anxiety levels assessed by the Anxiety Symptom Scale (SAST, p = 0.026) and quality of life assessed by the SF-36 (p < 0.001). Regarding the main study, eighty-eight T2DM patients completed the trial. Compared to control, glycated hemoglobin (HbA1c) levels showed a significant decrease (Δ%-change: -4.0% vs. 0.1%, p = 0.011). Quercetin also significantly improved PiKo-6 measurements (FEV1: 5.6% vs −1.5%, p = 0.002), systolic blood pressure (−5.0% vs −0.2%, p = 0.029), night sleep (11.6% vs −7.3%, p < 0.001), stress levels (SAST-10) (−26.2% vs 3.3%, p < 0.001) and quality of life (SF- 36) (physical and mental dimension, p < 0.001). Quantitative polymerase chain reaction (qPCR) analysis of genomic DNA extracted from whole blood samples of the 82 patients revealed a statistically significant increase in mean telomere length in the intervention group, while telomere length in the control group decreased (+0.52 kb vs. -0.31 kb, p = 0.048). Quercetin supplementation was associated with a significant increase in mean TL (odds ratio ≥ 2.44; p < 0.05) with a strengthened association after full adjustment for potential confounders through multiple logistic regression analysis (odds ratio = 3.48; p = 0.026), suggesting it as a potentially promising supplementation option. Conclusions: Through the interim analysis, positive evidence already emerged for a pleiotropic effect of quercetin intake in patients with T2DM. Especially, anxiety reduction and quality of life improvement were detected, in just 12 weeks of administration and without adverse effects. The potential health benefits associated with quercetin administration in patients with T2DM captured by this study, as evidenced by its emerging potential to significantly increase the average telomere length of the intervention group, along with an anti-hyperglycemic (HbA1c), normotensive (systolic BP), and increased one-second expiratory airflow (FEV1) effect that emerged warrant further investigation. Our findings also posit that quercetin supplementation may increase night-time sleep duration and positively impact anxiety burden and quality of life (QoL). These findings create possibilities for targeting disease progression and improving patient outcomes, although future larger-scale, multi-center, placebo-controlled, dose–response assessment and blinded studies are needed for validation. Importantly, our work indirectly showcases how lifestyle choices might affect the progression of T2DM and underscores the value of implementing TL measurements into clinical assessments for T2DM populations. Overall, based on the current open-label study, quercetin as a complementary phytonutritive senotherapy appears to be a promising supplement for T2DM, providing lifestyle and care support alongside standard pharmacological regimens. Additional investigations with varying quercetin dosages and durations are needed to establish its therapeutic potential and optimal parameters for health improvement and to shed light on long-term effectiveness and safety of quercetin. Further research is needed to shift this potential from clinical utility and feasibility to interdisciplinary evidence and to confirm this finding, elucidating the underlying molecular mechanisms of quercetin. We report that quercetin, alongside standard pharmacological regimens, might propose an integrative care plan, as evidenced by its emerging potential to significantly increase the average telomere length of the intervention group.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mantadaki, Aikaterini
  • Μανταδάκη, Αικατερίνη

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/57516

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mantadaki, Aikaterini; Μανταδάκη, Αικατερίνη. Μελέτη της ωφελιμότητας της λήψης κουερσετίνης (quercetin) σε διαβητικούς ασθενείς υπό αγωγή με αντιδιαβητικά δισκία: μία τυχαιοποιημένη προοπτική μελέτη δύο βραχιόνων (two –arm, prospective randomized control clinical trial) (interventional vs observation arm) στην Πρωτοβάθμια Φροντίδα Υγείας. University of Crete (UOC), 2024. http://hdl.handle.net/10442/hedi/57516